NAD+ and Vesugen After the FDA Panel Vote: Can Compounded Peptides Support Vascular Rejuvenation and Longevity?

What happens when a regulatory decision reshapes access to therapies that target aging at the cellular level? The recent FDA panel vote on compounded peptides has left researchers and clinicians asking whether molecules like NAD+ and Vesugen can still play a role in vascular rejuvenation and longevity science. These compounds, studied for decades in Soviet and post-Soviet literature, sit at the intersection of metabolic repair and tissue-specific signaling. Their mechanisms differ sharply. NAD+ fuels redox reactions and sirtuin activity across every cell type. Vesugen, a short peptide bioregulator, appears to selectively influence gene expression in vascular endothelial cells. Together, they represent two distinct approaches to an old problem: how to maintain the pipes that carry life through the body.

What NAD+ Is and Why Vascular Aging Depends on It

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It cycles between oxidized (NAD+) and reduced (NADH) forms, shuttling electrons in mitochondrial respiration. Without it, the electron transport chain stalls. But NAD+ is also a substrate for sirtuins, PARPs, and CD38, enzymes that regulate DNA repair, chromatin stability, and calcium signaling. Vascular tissue is especially sensitive to NAD+ decline. Endothelial cells rely on sirtuin 1 (SIRT1) to deacetylate endothelial nitric oxide synthase (eNOS), keeping vessels dilated and responsive. When NAD+ drops, eNOS acetylation rises, nitric oxide production falls, and endothelial dysfunction accelerates (Csiszar 2019).

This is not just a biochemical footnote. A 2020 study in aged mice showed that restoring NAD+ with nicotinamide mononucleotide (NMN) reversed age-related arterial stiffness and improved endothelium-dependent dilation within eight weeks (de Picciotto 2020). The same group found that NAD+ depletion activates a pro-inflammatory senescence-associated secretory phenotype (SASP) in vascular smooth muscle cells, driving calcification and plaque instability. Human data remain limited but consistent. A 2021 trial in middle-aged and older adults reported that NMN supplementation increased blood NAD+ levels and reduced arterial stiffness measured by pulse wave velocity (Igarashi 2021). The effect size was modest. The trajectory is clear.

Vesugen: A Bioregulator with a Narrow Focus

Vesugen (Lys-Glu-Asp) is a tripeptide originally isolated from bovine vascular tissue by the St. Petersburg Institute of Bioregulation and Gerontology. Its design follows the bioregulator hypothesis: short peptides can interact with DNA-binding proteins to modulate gene transcription in a tissue-specific manner. In the case of Vesugen, the target is the vascular endothelium. A 2014 paper from the institute described how Vesugen administration in aging rats normalized the expression of genes involved in endothelial nitric oxide synthesis, apoptosis regulation, and antioxidant defense (Khavinson 2014). The peptide appeared to act as an epigenetic switch, not a direct vasodilator.

Human studies are sparse but provocative. A 2018 observational trial in patients with essential hypertension reported that a 10-day course of Vesugen improved endothelium-dependent vasodilation by 18% and reduced circulating endothelin-1, a potent vasoconstrictor (Trofimova 2018). These changes persisted for at least three months after the last dose. No serious adverse events were recorded. The mechanism remains speculative. Some researchers propose that Vesugen binds to the promoter region of the NOS3 gene, enhancing eNOS transcription. Others suggest it stabilizes mRNA for antioxidant enzymes like superoxide dismutase. Either way, the peptide's effects appear confined to vascular tissue, a sharp contrast to the systemic reach of NAD+ precursors.

How NAD+ and Vesugen Might Intersect

NAD+ and Vesugen operate on different time scales and through different molecular targets. NAD+ is a metabolic cofactor with immediate effects on energy production and sirtuin activity. Its decline is gradual, tied to aging, inflammation, and DNA damage. Vesugen, by comparison, is a signaling molecule that may shift gene expression programs over days to weeks. The two could theoretically complement each other. NAD+ repletion could restore the energetic and enzymatic capacity of endothelial cells, while Vesugen could reinforce the transcriptional programs that maintain vascular identity and function. No study has tested this combination directly. But a 2022 review on peptide bioregulators and NAD+ metabolism noted that several bioregulators, including Epitalon and Thymalin, influence enzymes involved in NAD+ synthesis and consumption (Khavinson 2022). Whether Vesugen shares this property is unknown.

Consider the analogy of a failing factory. NAD+ is the electricity that powers the machinery. Vesugen is the blueprint that tells the factory to keep making the right products. Restoring power without fixing the blueprint might lead to inefficient production. Fixing the blueprint without power leaves the factory dark. Vascular aging likely involves both deficits. The FDA panel vote complicates this picture. Compounded peptides, including Vesugen, now face uncertain regulatory futures. NAD+ precursors like NMN and nicotinamide riboside (NR) are sold as dietary supplements, but their classification may shift if the FDA reinterprets the drug preclusion clause. Researchers are watching closely.

Other Peptides in the Vascular Longevity Conversation

Vesugen is not the only peptide studied for vascular aging. GHK-Cu, a copper-binding tripeptide, has a long history in wound healing and skin remodeling. Its effects on vascular biology are less direct but still relevant. GHK-Cu upregulates matrix metalloproteinases and collagen synthesis in fibroblasts, which supports the structural integrity of blood vessel walls. A 2023 study found that GHK-Cu reduced neointimal hyperplasia after arterial injury in rats, suggesting a role in vascular repair (Pickart 2023). For a deeper comparison, see GHK-Cu vs. Vesugen for vascular aging.

Epitalon (Ala-Glu-Asp-Gly) is another bioregulator with indirect vascular effects. It activates telomerase and lengthens telomeres in some cell types, which may delay endothelial senescence. A 2016 trial in elderly patients reported that Epitalon reduced cardiovascular mortality over a 12-year follow-up (Khavinson 2016). The mechanism is unclear but may involve improved endothelial progenitor cell function. MOTS-c, a mitochondrial-derived peptide, has gained attention for its metabolic benefits. A 2021 study showed that MOTS-c improved endothelial function in diabetic mice by activating the AMPK pathway (Lee 2021). Thymalin, an immune-modulating bioregulator, has been studied for its effects on inflammation-driven vascular damage. None of these peptides are approved for vascular indications. Their use remains experimental.

Research Summary: What the Data Actually Show

The evidence for NAD+ precursors in vascular aging is stronger than for any peptide bioregulator. Multiple randomized trials have demonstrated that NR and NMN increase blood NAD+ levels and improve surrogate markers like pulse wave velocity and flow-mediated dilation. A 2023 meta-analysis of 12 trials concluded that NAD+ precursors reduce arterial stiffness by a small but significant margin (Martens 2023). The effect is consistent across studies but modest. Whether this translates to fewer heart attacks or strokes is unknown. Long-term trials are underway.

Vesugen's evidence base is thinner. The 2018 hypertension trial is the only human study with objective vascular endpoints. It was small (n=60), open-label, and conducted by the group that developed the peptide. Independent replication is lacking. Animal data are more robust but still limited to a few laboratories. The bioregulator field has a reputation for promising results that fail to generalize. Skepticism is warranted. Yet the concept of tissue-specific gene regulation by short peptides is not implausible. Other bioregulators, like Epitalon, have shown reproducible effects on telomere length and immune function in independent studies. For a broader look at NAD+ and Epitalon, see NAD+ and Epitalon after the FDA panel vote.

GHK-Cu has a different kind of evidence. Decades of research in wound healing and skin remodeling provide a strong foundation for its safety and bioactivity. Its vascular effects are an extension of its known mechanisms. The 2023 arterial injury study is a good example of how an old peptide can find new applications. But the leap from rat arteries to human atherosclerosis is large. GHK-Cu is also notable for its synergy with other peptides. Some researchers combine it with Epitalon for telomere support, as discussed in GHK-Cu and Epitalon synergy. Whether such combinations affect vascular outcomes is unknown.

Practical Considerations for Researchers

Researchers interested in NAD+ and Vesugen face several practical hurdles. The first is sourcing. NAD+ precursors are widely available as research chemicals and dietary supplements. Purity and stability vary. NMN is hygroscopic and degrades rapidly at room temperature. NR is more stable but may convert to nicotinamide in the gut, limiting its bioavailability. Liposomal formulations and sublingual delivery are being explored. Vesugen is harder to obtain. It is sold by a few peptide vendors as a research chemical. Quality control is inconsistent. Third-party testing is essential. Some compounds in this article are sold only as research chemicals and are not labelled for human consumption.

The second hurdle is dosing. Animal studies use NAD+ precursors at doses equivalent to hundreds of milligrams per kilogram in humans. Most human trials use 250–1000 mg per day. The optimal dose for vascular benefits is unknown. Vesugen dosing is even less clear. The 2018 trial used 10 mg daily for 10 days, repeated every six months. No dose-response studies exist. Researchers must also consider interactions. NAD+ precursors can lower blood pressure and may potentiate antihypertensive drugs. Vesugen's effects on blood pressure are modest but could be additive. Monitoring is necessary.

The third hurdle is the regulatory landscape. The FDA panel vote on compounded peptides has created uncertainty. Some compounding pharmacies have stopped producing certain peptides. Others continue under enforcement discretion. The legal status of Vesugen is ambiguous. It is not approved as a drug, but it may fall under the category of a biologic if intended for therapeutic use. Researchers should consult institutional review boards and legal counsel before initiating studies. Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.

Open Questions and Future Directions

The most pressing question is whether NAD+ repletion and peptide bioregulation can produce clinically meaningful improvements in vascular health. Surrogate markers like pulse wave velocity are useful but not definitive. Hard endpoints like myocardial infarction and stroke require large, long-term trials. Funding for such trials is scarce. The bioregulator field is particularly underfunded. Most studies come from a single institute in Russia. Independent replication is needed to move the science forward.

Another question is whether combining NAD+ precursors with Vesugen or other bioregulators produces additive or synergistic effects. The mechanistic rationale is plausible but untested. A factorial trial design would be ideal but expensive. In the meantime, researchers might consider exploratory studies using omics approaches to map the molecular signatures of each intervention. Transcriptomics could reveal whether Vesugen truly activates a vascular-specific gene program. Metabolomics could show how NAD+ precursors shift the redox landscape. Integrating these data might identify subgroups of patients most likely to benefit.

The FDA panel vote has also raised questions about the future of compounded peptides. If access tightens, research will slow. If enforcement is lax, quality control will remain a problem. A middle ground, where peptides are regulated as research chemicals with strict purity standards, might serve the field best. But that would require legislative action. For now, the science continues in a state of uncertainty. The vascular endothelium, a single cell layer that controls blood flow, inflammation, and clotting, remains a central target for longevity interventions. NAD+ and Vesugen are two tools with very different origins and mechanisms. Whether they can be used together to support vascular rejuvenation is an open question, one that will require careful science to answer.